Event-Driven Stocks

Epizyme, Inc.

Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕

Signs● 3 good● 3 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY21FY20FY19FY18FY17FY16
Revenue$37.4M$1.4M$7.9M$12.0M$10.0M$8.0M
Operating income−$238.0M−$51.4M−$31.0M−$128.1M−$136.8M−$111.8M
Net income−$251.1M−$50.9M−$29.3M−$123.6M−$134.3M−$110.2M
Total assets$289.0M$473.6M$424.6M$275.5M$289.4M$252.4M
Total liabilities——————
Equity−$20.7M$184.9M$331.1M$233.0M$235.4M$201.7M
EPS (diluted)$-2.45$-0.51$-0.39$-1.72$-2.18$-1.93
Shares out.101.8M100.8M79.2M69.4M58.2M57.2M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2021
Operating margin
−635.9%
Net margin
−671.0%
Return on equity
1213.9%
Return on assets
−86.9%
Return on capital (ROCE)
−97.6%
Liabilities / assets
—
Debt / equity
—
Book value / share
$-0.20
Revenue growth (YoY)
2664.2%
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2021
Accruals / assets
−8.4%clean
Piotroski F-Score
3/8weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
54
/ 100
Profitability 20Growth 100Catalyst 33Earnings quality 67Financial strength 50

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 3 warning● 3 good
  • Negative shareholder equity
  • Operating losses (negative operating margin)
  • Reported a net loss
  • Negative operating cash flow
  • Strong return on equity (>15%)
  • Revenue is growing year-over-year
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

Clinical trials

ClinicalTrials.gov · ongoing · next readout first

Interventional studies led by this company. “Readout” is the trial's primary-completion date — an estimate the sponsor reports, not a guarantee.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (1)

Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.